Improved penicillin susceptibility of Streptococcus pneumoniae and increased penicillin consumption in Japan, 2013-18

PLoS One. 2020 Oct 22;15(10):e0240655. doi: 10.1371/journal.pone.0240655. eCollection 2020.

Abstract

Objectives: To examine the association between penicillin susceptibility of Streptococcus pneumoniae and penicillin consumption in Japan.

Methods: We used Japan Nosocomial Infection Surveillance data on the susceptibility of S. pneumoniae and sales data obtained from IQVIA Services Japan K.K. for penicillin consumption. We analysed both sets of data by decomposing them into seasonality and chronological trend components. The cross-correlation function was checked using Spearman's rank correlation coefficient to examine the correlation between susceptibility and consumption.

Results: After adjusting for seasonality, the susceptibility of S. pneumoniae to penicillins gradually improved (55.7% in 2013 and 60.6% in 2018, respectively) and penicillin consumption increased during the same period (0.76 defined daily doses per 1,000 inhabitants per day [DID] in 2013, and 0.89 DID in 2018). The results showed positive cross-correlation (coefficient 0.801, p-value < 0.001). In contrast, cephalosporin consumption decreased (3.91 DID in 2013 and 3.19 DID in 2018) and showed negative cross-correlation with susceptibility of S. pneumoniae to penicillins (coefficient -0.981, p-value < 0.001).

Conclusions: The rates of penicillin-susceptible S. pneumoniae isolates did not negatively correlate with penicillin consumption at the population level. Increased penicillin consumption might not impair the penicillin susceptibility of S. pneumoniae.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Cephalosporins / therapeutic use
  • Humans
  • Japan / epidemiology
  • Penicillin Resistance*
  • Penicillins / pharmacology*
  • Penicillins / therapeutic use
  • Pneumococcal Infections* / drug therapy
  • Pneumococcal Infections* / epidemiology
  • Streptococcus pneumoniae / drug effects*

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Penicillins

Grants and funding

Our study was supported by a grant from the Ministry of Health, Labour and Welfare (Grant number 20HA2003, changed from the previous one) and Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development (AMED) under grant number JP19fk0108061.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No author received a salary from the funders.